SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spitcoin is a community-driven cryptocurrency built on the Solana blockchain that powers a decentralized creator economy through the LimitlessFlo platform.  The project focuses on giving creators full control over their content and earnings by enabling instant monetization from day one—through tips, subscriptions, live streaming, and marketplace transactions—without the restrictions of traditional platforms like bans, algorithm suppression, or delayed payouts.  At its core, Spitcoin is about combining meme culture with real utility, creating a self-sustaining ecosystem where platform activity drives token demand, and token usage fuels platform growth.

SpitCoin

SpitCoin is gaining momentum as the community highlights its role in powering the LimitlessFlo ecosystem. Investors are actively drawing parallels between this project and other emerging crypto assets while calling for broader data integration across tracking platforms.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing heightened trading volume and speculative momentum as community members debate whether the project is at a technical breakout point or continuing a long-term decline. Investors are actively discussing the ecosystem's IoT and data ownership narratives while venting frustration over stalled price performance and the lack of recent communication from leadership.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community highlights significant supply locks and a long-term 'buy and hold' strategy, fueling bullish sentiment around the project's dedication and brand visibility. Investors are actively sharing positive conviction, often grouping the token with other Solana-based assets and emphasizing a unified, long-term mission.

LCX.com is a platform that innovates capital markets by providing solutions for compliant digital assets and security tokens. It is a secure and compliant platform for buying, selling, transferring, and storing digital currency.

LCX is generating significant community conversation as investors speculate on potential regulatory breakthroughs and upcoming platform catalysts, despite ongoing volatility and frustration over stagnant price action. While long-term bulls remain focused on the project's utility and institutional positioning, others are actively questioning its market performance and long-term viability compared to sector leaders.

Spire Global, Inc. collects space-based data using a proprietary constellation of low earth multi-use receiver nanosatellites. Its software analytics generate proprietary data, insights and predictive analytics for its customers through a subscription model. The company was founded by Peter Platzer in August 2012 and is headquartered in Vienna, VA.

Spire Global Inc - Ordinary Shares - Class A

Spire Global is generating significant momentum as the broader space sector attracts heavy institutional capital and speculative interest ahead of major launch milestones. The community remains focused on the company's dual-use defense and weather data analytics, debating the impact of recent government contract wins and pending financial reporting updates against the backdrop of potential industry-wide volatility.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is trending as investors debate whether the stock has hit a bottom following a steep decline, with many in the community pointing to strong customer loyalty and potential undervaluation compared to its historical performance. The conversation is currently split between those aggressively averaging down in anticipation of a rebound and critics questioning management's ability to drive share price appreciation despite consistent business operations.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Phoenix, AZ.

First Solar Inc

First Solar is attracting significant attention as investors view the company as a primary beneficiary of the massive energy demands driven by AI data centers and hyperscalers. Community sentiment remains focused on the company's strong domestic manufacturing moat and robust backlog, even as market volatility and analyst downgrades spark debate over the short-term impact of tariff policies and competitive pressures.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is generating significant community conversation as investors speculate on a breakout from its recent consolidation phase, with sentiment fueled by bullish expectations for ecosystem growth and broader crypto market momentum. Traders are actively debating technical levels while engaging with various memecoin projects on the network, signaling high participation and a focus on long-term adoption.

DigitalOcean Holdings, Inc. engages in the provision of providing cloud infrastructure. It operates through the following geographical segments: United States, Netherlands, Germany, Canada, Singapore, and Other. The company was founded in 2012 and is headquartered in Broomfield, CO.

DigitalOcean Holdings Inc

DigitalOcean is trending as investors focus on its pivot toward agentic AI infrastructure, with community discourse heavily influenced by strong institutional backing and a significant re-rating of its growth potential. The stock is being closely monitored for breakout setups as traders track its role in hosting high-performance AI inference workloads.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber is trending due to heightened investor focus on its 'brownfield' data center strategy following a massive multi-year compute contract that validates its specialized infrastructure approach. Community sentiment remains polarized, with some bulls emphasizing the company's high revenue per megawatt and low debt compared to peers, while skeptical traders frequently debate the management team's transparency and the stock's recent volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics (NASDAQ:CADL) Sets New 12-Month High  - Here's What Happened

Candel Therapeutics (NASDAQ:CADL) Hits New 52-Week High - What's Next...

Candel Therapeutics (CADL) to Release Earnings on Tuesday

Candel Therapeutics (NASDAQ:CADL) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-candel-therapeutics-inc-stock...

Candel Therapeutics (NASDAQ:CADL) Stock Price Up 6.1% - Should You Buy?

Candel Therapeutics (NASDAQ:CADL) Trading 6.1% Higher - Here's Why...

UCB To Acquire Candid Therapeutics For Up To $2.2 Bln To Boost Immunology Pipeline

(RTTNews) - United Community Banks, Inc. (UCB),on Sunday agreed to buy Candel Therapeutics, Inc. (CADL) for up to $2.2 billion, aiming to strengthen its pipeline of treatments for immune-related diseases...

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Candel Therapeutics ripped higher on Monday after a bullish analyst initiation, underscoring how narrative can outpace fundamentals.read more...

Candel Therapeutics (NASDAQ:CADL) Sees Large Volume Increase - Time to Buy?

Candel Therapeutics (NASDAQ:CADL) Sees Unusually-High Trading Volume - Should You Buy...

<ul class="summary-bullets"><li>The firm stated that the stock is deeply undervalued, with a discounted cash flow estimate of around $30 per share.</li><li>Investors are awaiting extended phase 3 data for CAN-2409 in prostate cancer, as well as from the late-stage trial in non-small cell lung cancer.</li><li>Last month, Candel reported encouraging results from a phase 2a clinical trial of CAN-2409 in non-small cell lung cancer.</li></ul>Shares of Candel Therapeutics (CADL) drew strong retail interest on Monday after a bullish brokerage call labeled the stock “significantly undervalued,” with optimism building ahead of key trial data in lung and prostate cancer.Cantor Fitzgerald initiated coverage of Candel Therapeutics with an “Overweight” rating, according to The Fly. The brokerage expressed strong confidence in the stock’s outlook, stating that the shares are “deeply undervalued”, pointing to a discounted cash flow (DCF) estimate of around $30 per share and peak sales potential of $2.4 billion in prostate cancer.This represents a potential 370% upside from the stock’s Friday closing price of $6.37, when the stock recorded its highest intraday gains in more than 16 months. <a href="https://stocktwits.com/symbol/CADL">CADL shares</a> traded 0.5% lower in Monday’s pre-market.Cantor said the bullish view is backed by positive Phase 3 data, clear regulatory progress under a Special Protocol Agreement, limited competition, and a manageable safety profile. Additional upside could come from the company’s lung cancer program, which is advancing into late-stage trials.<h2 class="st-heading-2">CAN-2409 Shows Promise</h2>Last month, Candel Therapeutics reported encouraging results from a phase 2a clinical trial of CAN-2409 in non-small cell lung cancer. After an additional year of follow-up, 50% of patients were still alive at two years, despite a poor response to prior treatments, the firm said.The therapy also showed improved survival compared with standard care and remained well-tolerated. Researchers found it helped activate the immune system and turn previously unresponsive tumors into ones that could respond to treatment.Extended phase 3 results for CAN-2409 in prostate cancer are <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-on-track-for-best-day-in-nearly-16-months-whats-driving-the-rally/cZJyGq6RIUn">expected</a> at the American Urological Association 2026 meeting in May. Investors in Candel Therapeutics are waiting for updates on its late-stage trial in non-small cell lung cancer and on other programs such as CAN-3110.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier. Message volume on the platform surged by around 70% over a 24-hour period, according to Stocktwits data.One user said the current share price offers a “tremendous opportunity.”<stembedurl>https://stocktwits.com/drizz/message/650754597</stembedurl>Year-to-date, the stock has gained around 7%.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/btc-price-dropping-another-3-000-could-wipe-out-all-ceasefire-gains/cZBdJ8WRIyt">BTC Price Dropping Another $3,000 Could Wipe Out All Ceasefire Gains, Analyst Warns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CADL Stock Gets A Bullish Call Just Weeks Before Crucial Prostate Cancer Data Reveal

Cantor Fitzgerald initiated coverage of Candel Therapeutics with an “Overweight” rating, according to The Fly.

CADL Stock Posted Its Best Day In Nearly 16 Months On Friday – Why Does Cantor See A Further 370% Upside?

Equity

<ul class="summary-bullets"><li>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma featured in Parade magazine.</li><li>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma.</li><li>New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.</li></ul>Shares of Candel Therapeutics (CADL) jumped 24% on Friday as investors await upcoming clinical data readouts and process positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.The stock is now on track to record its best day since December 2024, if gains hold.<h2 class="st-heading-2">Positive Media Coverage</h2>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma, featured in Parade magazine.Donahue, who was initially given only months to live after her diagnosis, participated in a clinical trial of the company’s investigational viral immunotherapy CAN-3110. Tak described the case as both deeply personal and scientifically meaningful, noting that such outcomes underscore the potential of viral immunotherapies to reshape the tumor microenvironment, activate durable immune responses, and represent a possible turning point in a disease where progress has long been elusive.<h2 class="st-heading-2">Upcoming Catalysts</h2>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma. New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.To add to the momentum, last month, the company announced positive updates for its lead candidate CAN-2409 in patients with advanced non-small cell lung cancer. The company said that extended long-term survival was observed after an additional year of follow-up in an ongoing phase 2a clinical trial, with 50% of 46 patients treated with CAN-2409 surviving beyond 24 months.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CADL stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.A few Stocktwits users expressed optimism for an upcoming buyout or partnership for the company.<stembedurl>https://www.stocktwits.com/drizz/message/650628803</stembedurl><stembedurl>https://www.stocktwits.com/gusm17/message/650618195</stembedurl>Another highlighted the positive press published on Parade, terming it “incredibly positive.”<stembedurl>https://www.stocktwits.com/pyroclast/message/650627286</stembedurl><a href="https://stocktwits.com/symbol/CADL">CADL stock</a> has gained 40% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/omer-stock-on-track-for-best-week-in-nearly-four-months-after-receiving-permanent-reimbursement-code-for-treatment/cZJUzYKRIUj">OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?

Candel stock is rallying on the heels of positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.  

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Hold" by Brokerages

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have earned a consensus recommendation of "Hold" from the eight analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and...

Candel Therapeutics (NASDAQ:CADL) Downgraded by Zacks Research to Strong Sell

Zacks Research downgraded Candel Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday...

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest CADL News

CADLCandel Therapeutics Inc